Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy

References

• Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013;190(2):441–449.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380(9858):2018–2027.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–962.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–250.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–2041. Erratum in: J Clin Oncol. 2007;25(26):4153.
   PubMed Web of Science ®Google Scholar
• Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299(23):2760–2769.
   PubMed Web of Science ®Google Scholar
• Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–428.
   PubMed Web of Science ®Google Scholar
• Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–756.
   PubMed Web of Science ®Google Scholar
• Deville C, Vapiwala N, Hwang WT, et al. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82(4):1389–1396.
   PubMed Web of Science ®Google Scholar
• Weiner AB, Matulewicz RS, Schaeffer EM, et al. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017;20(3):283–288.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):616–622.
   PubMed Web of Science ®Google Scholar
• Slater JD, Rossi CJ Jr, Yonemoto LT, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004;59(2):348–352.
   PubMed Web of Science ®Google Scholar
• Talcott JA, Rossi C, Shipley WU, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010;303(11):1046–1053.
   PubMed Web of Science ®Google Scholar
• Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69(2):444–453.
   PubMed Web of Science ®Google Scholar
• Weber DC, Zilli T, Vallee JP, et al. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: a treatment planning comparison study. Int J Radiat Oncol Biol Phys. 2012;84(3):e311–e318.
   PubMed Web of Science ®Google Scholar
• Swisher-McClure S, Yin L, Rosen M, et al. Prospective MRI-based imaging study to assess feasibility of proton therapy for post-prostatectomy radiation. Acta Oncol. 2016;55(7):828–833.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Common TerminologyCriteria for Adverse Events v4.0. NCI, NIH, DHHS. 29 May 2009. NIH publication # 09-7473.
   Google Scholar
• Barry MJ, Coffey DC, Fitzpatrick J, et al. Recommendations of the International Consensus Committee concerning patient evaluation for research studies. In: Cockett ATK, Aso Y, Chatelain C, et al., editors. Proceedings of the International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Islands: Paris Scientific Communication International; 1991. p. 279–281.
   Google Scholar
• Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319–326.
   PubMed Web of Science ®Google Scholar
• Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56(6):899–905.
   PubMed Web of Science ®Google Scholar
• Deville C, Both S, Bui V, et al. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon. Radiat Oncol. 2012;7:76.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361–368.
   PubMed Web of Science ®Google Scholar
• Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):383–387.
   PubMed Web of Science ®Google Scholar
• Kirk ML, Tang S, Zhai H, et al. Comparison of prostate proton treatment planning technique, interfraction robustness, and analysis of single-field treatment feasibility. Pract Radiat Oncol. 2015;5(2):99–105.
   PubMed Web of Science ®Google Scholar
• International Commission on Radiation Units and Measurements.Prescribing, recording, and reporting proton-beam therapy ICRU Report 78. Oxford: Oxford University Press; 2007.
   Google Scholar
• Jensen L, Yuh B, Wong JYC, et al. Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy. Adv Radiat Oncol. 2017;2(4):597–607.
   PubMedGoogle Scholar
• Cheung MR, Tucker SL, Dong L, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67(4):1059–1065.
   PubMed Web of Science ®Google Scholar
• Peeters ST, Hoogeman MS, Heemsbergen WD, et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;63(4):1142–1152.
   PubMed Web of Science ®Google Scholar
• Bryant C, Smith TL, Henderson RH, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):422–434.
   PubMed Web of Science ®Google Scholar
• Heemsbergen WD, Hoogeman MS, Hart GA, et al. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(4):1011–1018.
   PubMed Web of Science ®Google Scholar
• Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57(4):953–962.
   PubMed Web of Science ®Google Scholar
• Colaco RJ, Hoppe BS, Flampouri S, et al. Rectal toxicity after proton therapy for prostate cancer: an analysis of outcomes of prospective studies conducted at the university of Florida Proton Therapy Institute. Int J Radiat Oncol Biol Phys. 2015;91(1):172–181.
   PubMed Web of Science ®Google Scholar
• Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):596–602.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Munsell MF, Choi S, et al. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;87(5):946–953.
   PubMed Web of Science ®Google Scholar